Veralipride: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|A benzamide antipsychotic drug}} | |||
{{Drugbox | |||
| verifiedrevid = 477318123 | |||
| image = Veralipride.svg | |||
| image2 = Veralipride_molecule_ball.png | |||
| width = 200 | |||
}} | |||
Veralipride | '''Veralipride''' is a [[benzamide]] [[antipsychotic]] medication that was primarily used in the treatment of [[menopausal]] symptoms. It was marketed under the brand name ''Agreal'' and was available in several countries, including [[Spain]] and [[Italy]]. | ||
==Pharmacology== | ==Pharmacology== | ||
Veralipride is a [[dopamine antagonist]], which means it works by blocking the action | Veralipride is a [[dopamine antagonist]], which means it works by blocking [[dopamine]] receptors in the brain. This action is thought to help alleviate symptoms associated with [[menopause]], such as [[hot flashes]] and [[mood swings]]. | ||
==Uses== | |||
Veralipride was prescribed to manage [[vasomotor symptoms]] of menopause, which include hot flashes and night sweats. It was considered an alternative to [[hormone replacement therapy]] (HRT) for women who could not take HRT or preferred not to. | |||
==Side Effects== | ==Side Effects== | ||
The use of veralipride has been associated with several side effects, including [[drowsiness]], [[dizziness]], and [[gastrointestinal disturbances]]. More serious side effects include [[extrapyramidal symptoms]], which are movement disorders that can result from dopamine receptor blockade. | |||
== | ==Withdrawal and Controversy== | ||
Veralipride | Veralipride was withdrawn from the market in several countries due to concerns about its safety profile. Reports of [[psychiatric]] side effects, such as [[depression]] and [[anxiety]], led to increased scrutiny. In 2006, the [[European Medicines Agency]] (EMA) recommended the suspension of veralipride's marketing authorization in the [[European Union]]. | ||
== | ==Related pages== | ||
* [[Menopause]] | * [[Menopause]] | ||
* [[ | * [[Dopamine antagonist]] | ||
* [[ | * [[Extrapyramidal symptoms]] | ||
==References== | |||
{{Reflist}} | |||
[[Category:Antipsychotics]] | [[Category:Antipsychotics]] | ||
[[Category: | [[Category:Withdrawn drugs]] | ||
[[Category: | [[Category:Benzamides]] | ||
<gallery> | |||
File:Veralipride.svg|Veralipride chemical structure | |||
File:Veralipride_molecule_ball.png|Veralipride molecule ball-and-stick model | |||
</gallery> | |||
Latest revision as of 01:56, 17 February 2025
A benzamide antipsychotic drug
| Veralipride | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Veralipride is a benzamide antipsychotic medication that was primarily used in the treatment of menopausal symptoms. It was marketed under the brand name Agreal and was available in several countries, including Spain and Italy.
Pharmacology[edit]
Veralipride is a dopamine antagonist, which means it works by blocking dopamine receptors in the brain. This action is thought to help alleviate symptoms associated with menopause, such as hot flashes and mood swings.
Uses[edit]
Veralipride was prescribed to manage vasomotor symptoms of menopause, which include hot flashes and night sweats. It was considered an alternative to hormone replacement therapy (HRT) for women who could not take HRT or preferred not to.
Side Effects[edit]
The use of veralipride has been associated with several side effects, including drowsiness, dizziness, and gastrointestinal disturbances. More serious side effects include extrapyramidal symptoms, which are movement disorders that can result from dopamine receptor blockade.
Withdrawal and Controversy[edit]
Veralipride was withdrawn from the market in several countries due to concerns about its safety profile. Reports of psychiatric side effects, such as depression and anxiety, led to increased scrutiny. In 2006, the European Medicines Agency (EMA) recommended the suspension of veralipride's marketing authorization in the European Union.
Related pages[edit]
References[edit]
<references group="" responsive="1"></references>
-
Veralipride chemical structure
-
Veralipride molecule ball-and-stick model